New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds

References

• Link KP. The discovery of dicumarol and its sequels. Circulation. 1959;19:97–107.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107:1692–1711.
   PubMed Web of Science ®Google Scholar
• Hirsh J, O’Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation. 2007;116:552–560.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Anticoagulation – oral (clinical knowledge summary) 2016 [cited 2017 Apr 16]. Available from: https://cks.nice.org.uk/anticoagulation-oral
   Google Scholar
• Beyer-Westendorf J, Camm AJ, Coleman CI, et al. Rivaroxaban real-world evidence: validating safety and effectiveness in clinical practice. Thromb Haemost. 2016;116:S13–S23. Epub 2016/09/15.
   Web of Science ®Google Scholar
• Ageno W, Turpie AG. Spotlight on real-world evidence for the treatment of DVT: XALIA. Thromb Haemost. 2016;116:S41–S9.
   PubMed Web of Science ®Google Scholar
• Avgil-Tsadok M, Jackevicius CA, Essebag V, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2016;115:152–160. Epub 2015/ 09/12.
   PubMed Web of Science ®Google Scholar
• Pallister CJ, Watson MS. Haematology. 2nd ed. United Kingdom: Scion Publishing; 2010.
   Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Van der Hulle T, Kooiman J, Den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:320–328.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Pruthi RK, Patnaik MM. The new oral anticoagulants in clinical practice. Mayo Clin Proc. 2013;88:495–511.
   PubMed Web of Science ®Google Scholar
• Rao PSS, Burkart T. Advances in oral anticoagulation therapy – what’s in the pipeline? Blood Rev. 2017;31:205–211.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e120S–e151S.
   Web of Science ®Google Scholar
• Kearon C, Comp P, Douketis J, et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2005;3:962–968.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Takei R, Mohri M, et al. Antithrombotic effects of recombinant human soluble thrombomodulin (RHS-TM) on arteriovenous shunt thrombosis in rats. Am J Hematol. 1994;47:162–166.
   PubMed Web of Science ®Google Scholar
• Harker L, Marzec U, Mohri M, et al. Antithrombotic efficacy and safety of recombinant human soluble thrombomodulin in non-human primates: inactivation of thrombin and enhanced generation of activated protein C. Circulation. 2000; In press.
   Google Scholar
• Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069–2079.
   PubMed Web of Science ®Google Scholar
• Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.
   PubMed Web of Science ®Google Scholar
• Jacquemin M, Radcliffe CM, Lavend’homme R, et al. Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody. J Thromb Haemost. 2006;4:1047–1055.
   PubMed Web of Science ®Google Scholar
• Jacquemin M, Stassen JM, Saint-Remy J-M, et al. A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons. J Thromb Haemost. 2009;7:429–437.
   PubMed Web of Science ®Google Scholar
• Verhamme P, Pakola S, Jensen TJ, et al. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther. 2010;32:1205–1220.
   PubMed Web of Science ®Google Scholar
• Verhamme P, Tangelder M, Verhaeghe R, et al. Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial. J Thromb Haemost. 2011;9:664–671.
   PubMed Web of Science ®Google Scholar
• Thompson AR, Chen SH. Characterization of factor IX defects in hemophilia B patients. Methods Enzymol. 1993;222:143–146.
   PubMed Web of Science ®Google Scholar
• Srámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet. 2003;362:351–354.
   PubMed Web of Science ®Google Scholar
• Spanier TB, Oz MC, Minanov OP, et al. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg. 1998;115:1179–1188.
   PubMed Web of Science ®Google Scholar
• Toomey JR, Valocik RE, Koster PF, et al. Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. Stroke. 2002;33:578–585.
   PubMed Web of Science ®Google Scholar
• Refino CJ, Jeet S, DeGuzman L, et al. A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding. Arterioscler Thromb Vasc Biol. 2002;22:517–522.
   PubMed Web of Science ®Google Scholar
• Rusconi CP, Scardino E, Layzer J, et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 2002;419:90–94.
   PubMed Web of Science ®Google Scholar
• Dyke CK, Steinhubl SR, Kleiman NS, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006;114:2490–2497.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Lassen MR, et al. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008;6:457–463.
   PubMed Web of Science ®Google Scholar
• Ahmad SS, London FS, Walsh PN. Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface. J Thromb Haemost. 2003;1:2348–2355.
   PubMed Web of Science ®Google Scholar
• Rothlein R, Shen JM, Naser N, et al. TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two A/V shunt models without prolonging bleeding times. Blood. 2015;106:1886.
   Google Scholar
• Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30:382–387.
   PubMed Web of Science ®Google Scholar
• Bel A, Borik W, Davidson S, et al. Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. Eur J Cardiothorac Surg. 2016;49:682–689.
   PubMed Web of Science ®Google Scholar
• Chan MY, Rusconi CP, Alexander JH, et al. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost. 2008;6:789–796.
   PubMed Web of Science ®Google Scholar
• Povsic TJ, Vavalle JP, Aberle LH, et al. A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J. 2013;34:2481–2489.
   PubMed Web of Science ®Google Scholar
• Ahrens I, Putz V, Zelenkofske SL, et al. Abstract 9771: REG1, a novel RNA-aptamer direct factor IXa-inhibitor (pegnivacogin) reduces platelet activation in healthy volunteers and residual platelet aggregation in patients with ACS. A Radar substudy. Circulation. 2011;124:A9771.
   Web of Science ®Google Scholar
• Povsic TJ, Lawrence MG, Lincoff AM, et al. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin Immunol. 2016;138:1712–1715.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Mehran R, Povsic TJ, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet. 2016;387:349–356.
   PubMed Web of Science ®Google Scholar
• Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1:1504–1514.
   PubMed Web of Science ®Google Scholar
• Turpie AG, Eriksson BI, Lassen MR, et al. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc. 2002;11:182–188.
   PubMedGoogle Scholar
• Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood. 2001;97:2308–2313.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121:1523–1532.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). European Heart Journal. 2013;34:1498–1505. Epub 2013/03/15.
   PubMed Web of Science ®Google Scholar
• Palladino M, Merli G, Thomson L. Evaluation of the oral direct factor Xa inhibitor – betrixaban. Expert Opin Investig Drugs. 2013;22: 1465–1472. Epub 2013/08/24.
   PubMed Web of Science ®Google Scholar
• Abe K, Siu G, Edwards S, et al. Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral factor Xa inhibitor. Blood. 2006;108:901.
   Web of Science ®Google Scholar
• Cohen AT, Harrington R, Goldhaber SZ, et al. The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study. Am Heart J. 2014;167:335–341.
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101:68–76.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375:534–544.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Chi G, Halaby R, et al. Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX Trial substudy (acute medically ill venous thromboembolism prevention with extended duration betrixaban). Circulation. 2017;135:648–655.
   PubMed Web of Science ®Google Scholar
• FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. 2017 [cited 2017 Sep 1]. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564422.htm
   Google Scholar
• Kadokura T, Kashiwa M, Groenendaal D, et al. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. Biopharm Drug Dispos. 2013;34:431–441.
   PubMed Web of Science ®Google Scholar
• Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32:2541–2554.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Suzuki K, Kihara Y, et al. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica. 2013;43:534–547.
   PubMed Web of Science ®Google Scholar
• Iwatsuki Y, Sato T, Moritani Y, et al. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol. 2011;673:49–55.
   PubMed Web of Science ®Google Scholar
• Kaku S, Uemura T, Saitoh M, et al. Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis. Eur J Pharmacol. 2013;699:40–47.
   PubMed Web of Science ®Google Scholar
• Fuji T, Nakamura M, Takeuchi M. Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies. Clin Appl Thromb Hemost. 2014;20:199–211.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Agnelli G, Gallus AS, et al. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). Thromb Haemost. 2014;111:213–225.
   PubMed Web of Science ®Google Scholar
• Sakon M, Nakamura M. Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: phase III randomized, mechanical prophylaxis-controlled, open-label study. Thromb Res. 2012;130:e52–e59.
   PubMed Web of Science ®Google Scholar
• Lip GY, Halperin JL, Petersen P, et al. A phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2). J Thromb Haemost. 2015;13:1405–1413. Epub 2015/06/09.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. discontinues development of darexaban (YM150), an oral direct factor Xa inhibitor. 2011 [cited 2017 Aug 10]. Available from: https://www.astellas.com/en/corporate/news/pdf/110928_en.pdf
   Google Scholar
• Stringer F, Scott G, Kupfer S, et al. The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects. Br J Clin Pharmacol. 2010;70:305.
   Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48: 1–22. Epub 2008/12/17.
   PubMed Web of Science ®Google Scholar
• Kawamura M, Konishi N, Katsuhiko H, et al. Effects of TAK-442, a direct FXa inhibitor, and fondaparinux on platelet-associated prothrombinase in the balloon injured artery of rats. Blood. 2008;112:4077.
   Google Scholar
• Kawamura M, Konishi N, Hiroe K, et al. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. J Cardiovasc Pharmacol. 2010;56:156–161.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Cao C, Eriksson BI, et al. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010;104:1150–1157.
   PubMed Web of Science ®Google Scholar
• Goldstein S, Bates ER, Bhatt DL, et al. Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thromb Haemost. 2014;111:1141–1152.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Haas S, Ginsberg JS, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost. 2007;5:746–753.
   PubMed Web of Science ®Google Scholar
• Choi HY, Choi S, Kim YH, et al. Population pharmacokinetic and pharmacodynamic modeling analysis of GCC-4401C, a novel direct factor Xa inhibitor, in healthy volunteers. CPT Pharmacometrics Syst Pharmacol. 2016;5:532–543.
   PubMedGoogle Scholar
• Roffel A, Van Marle S, Choi S, et al. Metabolism and excretion of GCC-4401C, a factor Xa inhibitor, in humans. Int J. 2017;2:93–104.
   Google Scholar
• Cohen AT, Boyd RA, Mandema JW, et al. An adaptive-design dose-ranging study of PD 0348292, an oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery. J Thromb Haemost. 2013;11:1503–1510.
   PubMed Web of Science ®Google Scholar
• Xuan D, McBride S, Wastall P, et al. Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects. Clin Pharmacol Drug Dev. 2016;5:13–26.
   PubMed Web of Science ®Google Scholar
• Kohrt JT, Bigge CF, Bryant JW, et al. The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem Biol Drug Des. 2007;70:100–112.
   PubMed Web of Science ®Google Scholar
• McBane RD 2nd, Leadley RJ Jr., Baxi SM, et al. Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct factor Xa inhibitor, compared with antiplatelet agents in pigs. Arterioscler Thromb Vasc Biol. 2008;28:413–418.
   PubMed Web of Science ®Google Scholar
• Karnicki K, Leadley RJ Jr., Baxi S, et al. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis. Thromb Haemost. 2008;99:759–766.
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Zucker M, et al. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011;105:269–273.
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008;111:4113–4117.
   PubMed Web of Science ®Google Scholar
• Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696–701.
   PubMed Web of Science ®Google Scholar
• Cushman M, O’Meara ES, Folsom AR, et al. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood. 2009;114:2878–2883.
   PubMed Web of Science ®Google Scholar
• Renne T, Oschatz C, Seifert S, et al. Factor XI deficiency in animal models. J Thromb Haemost. 2009;7 Suppl 1:79–83.
   PubMed Web of Science ®Google Scholar
• Factor SU. XI deficiency in humans. J Thromb Haemost. 2009;7 Suppl 1:84–87.
   PubMed Web of Science ®Google Scholar
• Weitz JI. Factor XI and factor XII as targets for new anticoagulants. Thromb Res. 2016;141 Suppl 2:S40–S45.
   PubMed Web of Science ®Google Scholar
• Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116:4684–4692.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114:1729–1735.
   PubMed Web of Science ®Google Scholar
• Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123:2102–2107.
   PubMed Web of Science ®Google Scholar
• Crosby JR, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol. 2013;33:1670–1678.
   PubMed Web of Science ®Google Scholar
• Liu Q, Bethune C, Dessouki E, et al. ISIS-FXI Rx, a novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers. Blood. 2011; 118:209.
   Web of Science ®Google Scholar
• Buller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232–240.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116:3981–3989.
   PubMed Web of Science ®Google Scholar
• Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113:936–944.
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Watson CA, et al. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis. 2011;32:129–137.
   PubMed Web of Science ®Google Scholar
• Zeerleder S, Schloesser M, Redondo M, et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency – a study on 73 subjects from 14 Swiss families. Thromb Haemost. 1999;82:1240–1246.
   PubMed Web of Science ®Google Scholar
• Matafonov A, Leung PY, Gailani AE, et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood. 2014;123:1739–1746.
   PubMed Web of Science ®Google Scholar
• Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014;6:222ra17.
   PubMed Web of Science ®Google Scholar
• Woodruff RS, Xu Y, Layzer J, et al. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost. 2013;11:1364–1373.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 1998;97:544–552.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Deinum J, Mattsson C, Inghardt T, et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost. 2009;101:1051–1059.
   PubMed Web of Science ®Google Scholar
• Cullberg M, Wâhlander K, Jansson S, et al. Safety, pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor AZD0837 in young healthy volunteers. (Abstract 206). Basic Clin Pharmacol Toxicol. 2007;101:130.
   Google Scholar
• Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. 2009;30:2897–2907.
   PubMed Web of Science ®Google Scholar
• Pehrsson S, Johansson K, Kjaer M, et al. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. Thromb Haemost. 2010;104:1242–1249.
   PubMed Web of Science ®Google Scholar
• Walfridsson H, Johansson B, Englund A, et al. Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study. Clin Drug Investig. 2010;30:461–471.
   PubMed Web of Science ®Google Scholar
• Johansson S, Cullberg M, Eriksson UG, et al. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int J Clin Pharmacol Ther. 2011;49:258–267.
   PubMed Web of Science ®Google Scholar
• Olsson SB, Rasmussen LH, Tveit A, et al. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost. 2010;103:604–612. Epub 2010/01/16.
   PubMed Web of Science ®Google Scholar
• Lip GY, Rasmussen LH, Olsson SB, et al. Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation. Br J Clin Pharmacol. 2015;80:1362–1373.
   PubMed Web of Science ®Google Scholar
• Schutzer KM, Svensson MK, Zetterstrand S, et al. Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837. Eur J Clin Pharmacol. 2010;66:903–910.
   PubMed Web of Science ®Google Scholar
• Ellis DJ, Usman MH, Milner PG, et al. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009;120:1029–1035, 2 p following 1035. Epub 2009/09/10.
   PubMed Web of Science ®Google Scholar
• Bavisotto LM, Ellis DJ, Milner PG, et al. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011;51:561–574.
   PubMed Web of Science ®Google Scholar
• Albrecht D, Ellis D, Canafax DM, et al. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant. Thromb Haemost. 2017;117:706–717.
   PubMed Web of Science ®Google Scholar
• Choppin A, Irwin I, Lach L, et al. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. Br J Pharmacol. 2009;158:1536–1547.
   PubMed Web of Science ®Google Scholar
• Bowersox SS, Canafax D, Druzgala P, et al. Antithrombotic activity of the novel oral anticoagulant, tecarfarin [sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. Thromb Res. 2010;126:e383–e388.
   PubMed Web of Science ®Google Scholar
• Whitlock RP, Fordyce CB, Midei MG, et al. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial. Thromb Haemost. 2016;116:241–250.
   PubMed Web of Science ®Google Scholar
• Armetheon reaches agreement with FDA to conduct a 1000 patient single phase 3 study prior to NDA filing for its novel oral anticoagulant tecarfarin. 2017 [cited 2017 Aug 10]. Available from: https://armetheon.com/armetheon-reaches-agreement-with-fda-to-conduct-a-1000-patient-single-phase-3-study-prior-to-nda-filing-for-its-novel-oral-anticoagulant-tecarfarin/
   Google Scholar
• Ageno W, Büller HR, Falanga A, et al. Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost. 2016;116:1003–1010. Epub 2016/08/05.
   PubMed Web of Science ®Google Scholar
• Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35–44.
   PubMed Web of Science ®Google Scholar
• Schiele F, Van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–3562. Epub 2013/03/12.
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Lopez-Vilchez I, Molina P, et al. Idarucizumab fully restores dabigatran-induced alterations on platelet and fibrin deposition on damaged vessels: studies in vitro with circulating human blood. Blood. 2014;124:2878.
   Web of Science ®Google Scholar
• Grottke O, Van Ryn J, Spronk HM, et al. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care. 2014;18:R27.
   PubMed Web of Science ®Google Scholar
• Grottke O, Honickel M, Van Ryn J, et al. Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol. 2015;66:1518–1519.
   PubMed Web of Science ®Google Scholar
• Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943–951.
   PubMed Web of Science ®Google Scholar
• Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386:680–690.
   PubMed Web of Science ®Google Scholar
• Thakkar A Reversal of dabigatran etexilate: current strategies and the RE-VERSE AD trial: American College of Cardiology; 2015 [cited 2017 Jul 30]. Available from: http://www.acc.org/latest-in-cardiology/articles/2015/09/25/09/51/reversal-of-dabigatran-etexilate
   Google Scholar
• Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood. 2014;124:344.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015;114:198–205.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, Van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017;377:431–441. Epub 2017/07/12.
   PubMed Web of Science ®Google Scholar
• Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–451.
   PubMed Web of Science ®Google Scholar
• Crowther M, Kitt M, McClure M, et al. Abstract 10: randomized, double-blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors. Arterioscler Thromb Vasc Biol. 2013;33:A10.
   Google Scholar
• Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–2424.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Milling TJ Jr., Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–1141.
   PubMed Web of Science ®Google Scholar
• Muralidharan-Chari V, Mousa SA. Ciraparantag. Heparin neutralizer, anticoagulant reversal agent. Drugs Fut. 2016;41:341.
   Web of Science ®Google Scholar
• Laulicht B, Bakhru S, Lee C, et al. Small molecule antidote for anticoagulants. Circulation. 2012;126:A11395–A.
   Web of Science ®Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117:238–245.
   PubMed Web of Science ®Google Scholar
• Laulicht B, Bakhru S, Steiner S, et al. PER977 (ciraparantag) reverses edoxaban anticoagulation at steady state and has no effect on re-anticoagulation at the next scheduled dose. Eur Heart J. 2015;36:859–860.
   Web of Science ®Google Scholar
• Lip GYH, Freedman B, De Caterina R, et al. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117:1230–1239. Epub 2017/06/10.
   PubMed Web of Science ®Google Scholar
• Freedman B, Lip GY. ‘Unreal world’ or ‘real world’ data in oral anticoagulant treatment of atrial fibrillation. Thromb Haemost. 2016;116:587–589.
   PubMed Web of Science ®Google Scholar
• Carmo J, Moscoso Costa F, Ferreira J, et al. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost. 2016;116:754–763.
   PubMed Web of Science ®Google Scholar